Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.

Frontiers in immunology - 1 Jan 2026

Mahmood Umair, Bhan Chetan, Imber Charles, Murphy Jamie, Menon Krish, Barwick Tara D, Amin Zahir, Khan Khurum

Abstract excerpt

Patients with unresectable Gastrointestinal cancers (GI) including advanced colorectal cancer (CRC) and gall bladder cancer (GBC) have limited treatment options. Treatment with chemotherapy is associated with limited success resulting from therapeutic resistance. Immune checkpoint inhibitors are effective for a subset of metastatic CRC (5% with MSI-H status) and up to 30% of patients with GBC. Therefore, there is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to Gastrointestinal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Liquid Biopsy

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41782871
DOI: 10.3389/fimmu.2026.1738295
PMCID: PMC12953476

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy.PMID 41782871Read ↗

Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

Tumors of the Digestive System: Comprehensive Review of Ancillary Testing and Biomarkers in the Era of Precision Medicine.Semantic proximity Read ↗

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursSemantic proximity Read ↗

Molecular targets in GI malignancies - A pathologist's perspective.Semantic proximity Read ↗

ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.Semantic proximity Read ↗

Molecular Advances in Gastrointestinal Pathology.Semantic proximity Read ↗

The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.Semantic proximity Read ↗

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.Semantic proximity Read ↗

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.Semantic proximity Read ↗

Impact of tissue-agnostic approvals for patients with gastrointestinal malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.